How Clovis’ Rociletinib And AstraZeneca’s AZD9291 Development Programs Stack Up
Clovis and AstraZeneca have kept pace regarding submissions of breakthrough EGFR inhibitors rociletinib and AZD9291, but clinical trial programs suggests the big pharma is far ahead in overall development.
You may also be interested in...
AstraZeneca sees an edge on safety for Iressa, which was traditionally perceived as having attractive tolerability relative to other EGFR inhibitors, but firm still has a tough road competing against the omnipresent Tarceva.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.